Takeda’s Entyvio Receives Historic Patent Term Adjustment in China, a First for the Country
On August 16, a significant milestone was reached as the China National Intellectual Property Administration...
NHSA Updates NRDL Review, Adds Three Domestic Western Medicines
The National Healthcare Security Administration (NHSA) has issued a notification regarding the review and correction...
Regeneron Secures EU Approval for Ordspono, Its First Bispecific Antibody
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) has secured its first global market approval for Ordspono (odronextamab)...
BeiGene Positions for Global Growth with Strong Half-Year Results and R&D Investment
BeiGene (NASDAQ: BGNE; HKG: 6160; SHA: 688235) reported robust second-quarter 2024 results, highlighting significant corporate...
Peking Union Medical College Innovates with Angle Positioning Device Patent Sale
Peking Union Medical College Hospital (PUMCH) has announced its intention to transfer the patent for...
China’s WORK Medical Technology Targets U.S. Market with Upcoming IPO
China-based WORK Medical Technology Group Ltd has priced its initial public offering (IPO) at USD...
UCB Agrees to USD 680 Million Divestment of China Neurology and Allergy Business to CBC Group and Mubadala
UCB, a Belgium-based biopharmaceutical company listed on the Brussels Stock Exchange (FRA: UNC), has announced...
Shenzhen Salubris Pharmaceuticals Inks Licensing Deal for YolTech Therapeutics’ YOLT-101 Gene Editing Therapy
Shenzhen Salubris Pharmaceuticals Co., Ltd, a Chinese pharmaceutical company listed on the Shenzhen Stock Exchange...
Shanghai Fudan-Zhangjiang Enrolls First Patient in Phase III Trial for TROP2 ADC FDA018 in TNBC
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd, a China-based pharmaceutical company listed on the Hong Kong Stock...
China’s Guilin Sanjin Pharmaceutical Advances BC011 with NMPA Approval for Phase I Clinical Trial
Guilin Sanjin Pharmaceutical Co. Ltd, a Chinese pharmaceutical company listed on the Shenzhen Stock Exchange...
Guangzhou Boji Medical and CapitalBio Pharma Form Joint Venture to Innovate in Traditional Chinese Medicine
Guangzhou Boji Medical Biotechnological Co., Ltd, a Clinical Research Organization (CRO) based in China and...
Shanghai Henlius Biotech Reports 9.8% YOY Revenue Growth and Continued Profitability in 2024H1 Financial Report
Shanghai Henlius Biotech Inc., a biopharmaceutical company based in China and listed on the Hong...
Changchun High & New Technology Industries Receives FDA Approval for GenSci098 Clinical Trial in Thyroid Eye Disease
Changchun High & New Technology Industries (Group) Inc., a Chinese corporation listed on the Shenzhen...
Diversifying HPV Protection: Beijing Wantai’s Vaccine Filing Competes with Gardasil 9 in China
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd, a Chinese pharmaceutical company listed on the Shanghai...
BeiGene Advances R/R CLL/SLL Treatment with FDA Fast-Tracked BGB-16673 in Phase I/II Clinical Trial
BeiGene (NASDAQ: BGNE; HKG: 6160; SHA: 688235), a leading biopharmaceutical company, has been granted Fast...
MicroPort Endovascular MedTech Reports 26.63% YOY Revenue Growth and Strong R&D Investment in 2024H1
Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016), a Chinese endovascular device manufacturer, has reported...
Shanghai Pharmaceuticals Posts 5.14% YOY Revenue Growth in 2024H1 with Focus on Cell Therapies
Shanghai Pharmaceuticals Holding Co. (SPH; HKG: 2607; SHA: 601607) has announced its financial results for...
Innovent Biologics’ President Liu Yongjun Resigns, CEO De-Chao Micheal Yu Takes R&D Reins
Innovent Biologics Inc., a leading biopharmaceutical company based in China and listed on the Hong...
Fosun Pharma’s Privatization of Henlius Includes Cash and Share Offers, Aims for Full Equity Control
Shanghai Fosun Pharmaceutical (Group) Co., Ltd, listed on the Shanghai Stock Exchange (SHA: 600196) and...
China’s CDE Approves Multitude Therapeutics’ AMT-676 for Clinical Study in Solid Tumors
The Center for Drug Evaluation (CDE) of China has granted clinical study approval for Multitude...